权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

COBRE Center for Antimicrobial Resistance and Therapeutic Discovery

COBRE 抗菌素耐药性和治疗发现中心

基本信息

批准号：
10488596
负责人：
ERIKA M D'AGATA
金额：
$ 183.2万
依托单位：
MIRIAM HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-18 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10488596
关键词：
Antibiotic Resistance Antibiotics Antimicrobial Resistance Bacterial Antibiotic Resistance Biomedical Research Biotechnology Centers of Research Excellence Cessation of life Chemotherapy-Oncologic Procedure Clinical Clinical Medicine Communicable Diseases Communities Core Facility Dedications Discipline Ensure Environment Faculty Financial Hardship Fostering Funding Generations Goals Healthcare Hospital Costs Hospitals Infection Infrastructure Institution International Intervention Investments Laboratories Laboratory Research Longevity Medical Mentors Organ Transplantation Participant Pharmaceutical Preparations Pharmacologic Substance Phase Pilot Projects Primary Health Care Program Development Research Research Personnel Resistance Resort Resources Rhode Island Services Therapeutic Training Support United States Universities Work antimicrobial drug career career development clinical practice cost design drug discovery drug resistant pathogen innovation microorganism multidisciplinary novel strategies novel therapeutic intervention novel therapeutics programs resistance mechanism success

项目摘要

Project Summary: Overall Resistance to antimicrobial therapies is a national and international crisis that threatens clinical practice from fundamental primary care to the most advanced medical interventions such as cancer chemotherapy and organ transplantation. Much of what we take for granted in clinical medicine could become too risky as microorganisms have become increasingly resistant to our newest medications and our antibiotics of last resort. Antimicrobial resistance also adds enormous costs to health care, exceeding $21 billion in the United States alone. Compounding this problem is the fact that pharmaceutical companies have largely abandoned antibiotic development programs. As an alternative to large pharmaceutical companies, academic institutions and biotech startups can step in to refill the antibiotic pipeline using novel approaches to drug discovery. The principal objective of this Phase I COBRE application is to build a unique, multi-disciplinary center of excellence to study mechanisms of antimicrobial resistance and develop therapeutic countermeasures. The long-term goal of the Center for Antimicrobial Resistance and Therapeutic Discovery (CARTD) at The Miriam Hospital of the Lifespan Hospital Group is to develop new therapies for infections caused by drug resistant pathogens. This long-term goal will be attained with shorter-term objectives of developing a new generation of junior investigators who study mechanisms of resistance, characterize new targets, and study new and existing compounds. CARTD will integrate their work with mentors and established investigators at the institution and develop core facilities to enhance research capabilities in the field of antimicrobial resistance and the discovery of new therapeutics. To achieve these objectives, the CARTD will complete the following specific aims: 1. Consolidate existing researchers into a dynamic, interactive center of excellence across The Miriam Hospital, and its academic partners in Rhode Island, including Brown University. 2. Foster the research programs and career development of junior investigators in the field of antimicrobial resistance and studies of novel therapeutic approaches. 3. Support new institutional research with pilot project funding. 4. Establish critical infrastructure with new core laboratories to facilitate cutting edge research in antimicrobial resistance and therapeutic discovery, and serve as a unique technical resources to other COBRE research programs, other institutional researchers, and investigators in the region.

项目概要：总体抗菌药物耐药性是一个国家和国际危机，威胁到临床实践，从基本的初级保健到最先进的医疗干预，如癌症化疗，器官移植我们在临床医学中认为理所当然的许多事情可能会变得过于危险，微生物对我们最新的药物和抗生素的抗药性越来越强。度假村.抗生素耐药性也给医疗保健增加了巨大的成本，在美国超过210亿美元。只有国家。使这一问题更加复杂的是，制药公司在很大程度上放弃了抗生素开发计划。作为替代大型制药公司、学术机构生物技术初创公司可以介入，使用新的药物发现方法重新填充抗生素管道。的 COBRE第一阶段应用的主要目标是建立一个独特的、多学科的中心，研究抗菌素耐药性机制和制定治疗对策。的米里亚姆抗菌素耐药性和治疗发现中心（CARTD）的长期目标 Lifespan医院集团的医院正在开发新的治疗耐药引起的感染的方法。病原体这一长期目标将通过开发新一代初级研究人员，他们研究耐药机制，描述新靶点，研究新的和现有的化合物. CARTD将把他们的工作与导师和机构的既定调查人员结合起来，发展核心设施，以提高抗菌素耐药性领域的研究能力，新的治疗方法。为达致这些目标，本中心将完成以下具体目标：1. 将现有的研究人员整合成一个充满活力的，互动的卓越中心，横跨米里亚姆医院，以及它在罗得岛的学术合作伙伴，包括布朗大学。2.促进研究项目，初级研究人员在抗菌素耐药性领域的职业发展和新的治疗方法。3.通过试点项目资金支持新的机构研究。4.建立关键新的核心实验室的基础设施，以促进抗菌素耐药性的前沿研究，治疗发现，并作为一个独特的技术资源，以其他COBRE研究计划，其他机构研究人员和该地区的调查人员。